Literature DB >> 2418285

Kinetic disposition and hemodynamic effects of tetrandrine in anesthetized dogs.

F D Zeng, D H Shaw, R I Ogilvie.   

Abstract

The kinetic disposition and hemodynamic effects ot tetrandrine, l3 mg/kg i.v., over 30 s were studied in five anesthetized dogs during continuous monitoring of the ECG and systemic arterial pressure. Repeated determinations of cardiac output (CO) and pulmonary capillary wedge pressure (PCWP) were made via a flow-directed thermodilution catheter in the pulmonary artery. Blood samples were drawn at intervals for determination of plasma tetrandrine or erythrocyte binding of the drug. Maximal reductions in mean and diastolic arterial pressures of 23 +/- 4% were observed within 5 min of the drug infusion without a change in systolic pressure. CO was increased maximally 52% and systemic resistance reduced 5l% at l0 min, gradually returning to baseline values in l-2 h. PCWP was increased transiently at 5-l0 min. The PR interval was prolonged slightly without alteration in the R-R interval, QRS, or QTc. Changes in MAP and PR interval were correlated significantly with plasma tetrandrine concentrations over time, which followed a two-compartment kinetic model with a distribution t1/2 of 7 min and an elimination tl/2 of 88 min. The apparent volume of distribution at steady state was 57 L/kg. Plasma tetrandrine was greater than 90% bound to plasma proteins, and approximately 44% of whole blood tetrandrine was associated with erythrocytes. Tetrandrine is a potent arteriolar vasodilator drug with slight effects on AV conduction, but without significant negative inotropic effects in anesthetized dogs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2418285     DOI: 10.1097/00005344-198511000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Tetrandrine blocks a slow, large-conductance, Ca(2+)-activated potassium channel besides inhibiting a non-inactivating Ca2+ current in isolated nerve terminals of the rat neurohypophysis.

Authors:  G Wang; J R Lemos
Journal:  Pflugers Arch       Date:  1992-09       Impact factor: 3.657

2.  Mechanisms of action of 7-O-ethyl tetrandrine in isolated vascular smooth muscle of the rabbit aorta.

Authors:  J Y Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-04       Impact factor: 3.000

Review 3.  A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).

Authors:  Yueping Jiang; Min Liu; Haitao Liu; Shao Liu
Journal:  Phytochem Rev       Date:  2020-04-24       Impact factor: 5.374

Review 4.  Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.

Authors:  Paula M Heister; Robin N Poston
Journal:  Pharmacol Res Perspect       Date:  2020-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.